Navigation Links
Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) (MP-376) Treatment in Cystic Fibrosis Patients
Date:9/10/2009

onths. Patients were also allowed to remain on all other stable CF therapies during the study.

"The results of this study are very gratifying, particularly given the heavily treated nature of the patients included in this trial," stated Dr. Jeff Loutit, Chief Medical Officer of Mpex Pharmaceuticals. "It is difficult for new agents to show benefit on top of state-of-the-art care in CF, and generating statistically significant results across a broad range of key endpoints in this Phase 2b study bodes well for success in Phase 3."

"We thank the participating CF patients and physicians for helping make this trial a success," stated Daniel Burgess, President and CEO of Mpex Pharmaceuticals. "We are eager to meet with CF experts and regulatory authorities in the U.S. and Europe to discuss these results and determine the most expeditious path to move Aeroquin through Phase 3 development."

Patients with CF suffer from chronic infections of the lower respiratory tract that can be caused by multiple bacteria, including P. aeruginosa. Chronic pulmonary infection is associated with a decrease in lung function over time caused by inflammation arising from bacteria and their toxins. Periodic exacerbations in the lung result from bacterial overgrowth, and these exacerbations are implicated as a major cause of morbidity and mortality in CF patients.

About Aeroquin (MP-376)

MP-376 is a proprietary formulation of levofloxacin that has been optimized for aerosol delivery using a customized Investigational eFlow(R) Nebulizer System (PARI Pharma GmbH). Levofloxacin is a fluoroquinolone antibiotic that has been widely used in a variety of indications for over a decade and has established safety and efficacy when administered orally or intravenously against many bacterial pathogens, including P. aeruginosa. Administration of MP-376 with a high efficiency nebulizer to th
'/>"/>

SOURCE Mpex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer
2. Rib-X Pharmaceuticals to Present at the 49th ICAAC
3. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
4. Dont Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains
5. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
6. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
7. Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet
8. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
9. Alexza Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
10. Trubion Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
11. Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015  HealthSouth Corporation (NYSE: ... of post-acute healthcare services, offering both facility-based and ... operations for the second quarter ended June 30, 2015. ... by strong volume growth in both segments and ... Jay Grinney, President and Chief Executive Officer of ...
(Date:7/29/2015)... Inc., an early stage biotech startup based on perinatal ... the Musculoskeletal Transplant Foundation of Edison NJ ... round of development of the proprietary AmnioCept™ product line ... AmnioChor,s technology allows cryopreservation of the amniotic membrane of ... those tissues. Amnion is a well-established source of multipotent ...
(Date:7/29/2015)... VANCOUVER , July 29, 2015 /PRNewswire/ - RepliCel ... clinical stage regenerative medicine company, is pleased to announce ... dermal injector (RCI-02) have been locked.  Prototypes for ... to prepare for an application for CE mark ... Europe in 2016. (Photo: ...
(Date:7/29/2015)... TX (PRWEB) , ... July 29, 2015 , ... Costello ... new levee system to protect the Orange County, Texas area from future storm ... multi-firm design team in determining several potential levee alignment alternatives for providing protection, Costello ...
Breaking Biology Technology:HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31HealthSouth Reports Results for Second Quarter 2015 32HealthSouth Reports Results for Second Quarter 2015 33HealthSouth Reports Results for Second Quarter 2015 34HealthSouth Reports Results for Second Quarter 2015 35HealthSouth Reports Results for Second Quarter 2015 36
... now market product to poultry, red meat and pork processing ... ... N.J., May 19 Tasker Products Corp.,(OTC Bulletin Board: TKER), a ... announced,that it has received authorization from the Food Safety and Inspection,Service ...
... HALO System Demonstrated for, Eradicating Barrett,s Esophagus and ... May 19 Booth #2349 -- Digestive Disease ... the design and manufacture,of medical devices for digestive ... entitled, "A Randomized, Multicenter, Sham-Controlled,Trial of Radiofrequency Ablation ...
... PACS and Practice Management Software Adds ... Philips Ultrasound with Acquisition, ... Systems, a,leading developer of digital radiography (DR), PACS (Picture ... care practices, announced it has completed its acquisition of,Ultrasource, ...
Cached Biology Technology:Tasker Products Receives Authorization from USDA for its Tasker Clear for use in Meat and Pork Industries 2Tasker Products Receives Authorization from USDA for its Tasker Clear for use in Meat and Pork Industries 3Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus 2Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus 3Eklin Announces Acquisition of Ultrasource, Inc. 2Eklin Announces Acquisition of Ultrasource, Inc. 3
(Date:7/21/2015)... 2015 Passwords have proven futile for ... recent U.S. Office of Personnel Management breach. Biometric ... conundrum, but developers and end-users are concerned about ... dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today the ... third party integration. A video ...
(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... CORVALLIS, Ore. A new review suggests that omega-3 fatty ... certain situations, and that dietary standards based on the best ... a slam dunk a few years ago may not be ... professor in OSU,s College of Public Health and Human Sciences ...
... usually brings to mind vivid images of shattered concrete ... the result of violent hurricanes, massive earthquakes, or rampaging ... natural disaster in U.S. history ravaged the Midwest in ... of this disaster? Water scarcity. Drought during this period ...
... With Halloween just a few days away, millions are flocking ... of terror. The latest video from the American Chemical Society,s ... sense of fear. The episode is available now at ... anticipation of possible harm We know that the body is ...
Cached Biology News:Excess omega-3 fatty acids could lead to negative health effects 2Excess omega-3 fatty acids could lead to negative health effects 3New book addresses consequences of drought in arid regions 2New book addresses consequences of drought in arid regions 3
versican (H-56)...
... degrades single-stranded DNA and RNA endonucleolytically ... acids (DNA:DNA, DNA:RNA or RNA:RNA) are ... high concentrations of enzyme (1). The ... termini from double-stranded DNA (2), for ...
... catalyzes the transfer of the ... 5-terminus of polynucleotides or to ... The enzyme, purified from recombinant ... to phosphorylate RNA, DNA and ...
... verticillus USBio Analyzed PRODUCT SPECIFICATIONS Form: White powder Assay: 1.5 ... units/ml): 4.5 to 6.0 Loss On Drying: less than or ... 0.1% Bleomycin Content: A 2 : 55 - 70% B ... : greater than or equal to 90% B 4 : ...
Biology Products: